# Oliver’s Law: Campaign Calls for Changes to Medical Cannabis Prescribing in Psychiatric Conditions > **Author:** Benjamin Caplan, MD (ABFM Board Certified, MA Lic. #240562, NPI: 1962722637) > **Publisher:** CED Clinic (https://cedclinic.com) > **Canonical URL:** https://cedclinic.com/psychiatric-cannabis-prescribing-guidelines-olivers-law/ > **Published:** 2026-04-02T12:50:29-04:00 | **Last Modified / Clinically Audited:** 2026-09-28T10:32:06-04:00 > **Clinical Summary:** Explore psychiatric cannabis prescribing guidelines and Oliver's Law campaign advocating evidence-based changes for medical cannabis use in psychiatric conditions. --- ✦ New CED Clinical Relevance #72 Notable Clinical Interest Emerging findings or policy developments worth monitoring closely. Mental HealthPolicyResearchSafety Why This Matters Clinicians treating psychiatric patients need clarity on evidence standards for cannabis because patients are increasingly self-medicating or seeking prescriptions despite limited RCT data, creating liability and safety gaps in clinical decision-making. Oliver’s Law highlights the disconnect between anecdotal patient reports of symptom improvement and the rigorous evidence required for responsible prescribing, forcing psychiatrists to establish evidence-based protocols rather than relying on patient testimonials alone. Regulatory changes advocated in this campaign could establish clearer prescribing guidelines, enabling clinicians to either confidently recommend cannabis for specific psychiatric conditions or transparently explain to patients why evidence remains insufficient. Clinical Summary Oliver’s Law represents a public health advocacy campaign addressing a significant evidence gap in psychiatric cannabis use, where anecdotal patient reports of benefit substantially outpace the rigorous clinical trial data supporting such treatment. Despite widespread patient claims of symptom relief for conditions including anxiety, depression, and PTSD, the randomized controlled trial evidence base remains sparse, creating a disconnect between clinical practice and evidence-based medicine in this domain. The campaign advocates for regulatory and policy changes that would facilitate more robust [clinical research](https://cedclinic.com/cannabis-based-therapies-smoking-cessation/) into cannabis efficacy and safety in psychiatric populations, potentially including streamlined approval pathways for investigational studies and insurance coverage for evidence-gathering trials. For clinicians, this initiative highlights the current uncertainty surrounding psychiatric cannabis prescribing and underscores the need for cautious, individualized patient assessment while advocating for expanded research funding. Patients seeking cannabis for psychiatric symptoms should understand that while real-world reports are encouraging, the clinical evidence remains preliminary and that participation in rigorous trials could accelerate knowledge development. Clinicians should engage with patients about this evidence gap transparently while considering cannabis as an option only after discussion of risk-benefit ratios and in conjunction with established psychiatric treatments. Dr. Caplan’s Take “We’re in a difficult position where patients are clearly using cannabis for psychiatric symptoms and many report meaningful relief, yet our evidence base remains frustratingly thin, which is why I tell patients the honest truth: we have clinical observation but not robust trial data, and until we fund serious research into dosing and drug interactions in this population, psychiatric cannabis use will remain more art than medicine.” Clinical Perspective Although patients with psychiatric conditions frequently report symptomatic relief with cannabis use in observational studies, the evidence base for [medical cannabis](https://cedclinic.com/therapeutic-benefits-of-thc/) in psychiatry remains sparse, with few rigorous randomized controlled trials to date. The disconnect between patient-reported outcomes and limited clinical trial data creates genuine uncertainty for prescribers about efficacy, optimal dosing, and long-term safety, particularly given cannabis’s complex pharmacology and variable THC/CBD ratios across products. Clinicians should remain aware that subjective improvement in symptoms may reflect placebo effects, natural disease fluctuation, or concurrent treatments rather than direct cannabinoid action, while potential harms including psychosis risk, cognitive effects, and drug interactions are inadequately characterized in psychiatric populations. Until higher-quality evidence emerges, a cautious, individualized approach is warranted: document clear psychiatric indications, establish baseline symptom severity and functional status, use validated outcome measures to track response, and consider cannabis only 💬 Join the Conversation Have a question about how this applies to your situation? [Ask Dr. Caplan →](https://benjamincaplan.com/ask-dr-caplan) Want to discuss this topic with other patients and caregivers? [Join the forum discussion →](https://cedclinic.com/interact/discussion-forums/forum/mental-health/) Have thoughts on this? Share it: [𝕏 Share on X](https://twitter.com/intent/tweet?text=Just+read+this+on+CEDclinic.com%3A+Oliver%27s+Law%3A+Campaign+Calls+for+Changes+to+Medical+Cannabis+Prescribing+in+Psychiatric+Conditions+%40drcaplan&url=https%3A%2F%2Fcannabishealthnews.co.uk%2F2026%2F04%2F01%2Folivers-law-campaign-could-reshape-medical-cannabis-prescribing%2F)[in Share on LinkedIn](https://www.linkedin.com/sharing/share-offsite/?url=https%3A%2F%2Fcannabishealthnews.co.uk%2F2026%2F04%2F01%2Folivers-law-campaign-could-reshape-medical-cannabis-prescribing%2F)[🦅 Share on BlueSky](https://bsky.app/intent/compose?text=Just+read+this%3A+Oliver%27s+Law%3A+Campaign+Calls+for+Changes+to+Medical+Cannabis+Prescribing+in+Psychiatric+Conditions+--+via+%40drcaplan.bsky.social+https%3A%2F%2Fcannabishealthnews.co.uk%2F2026%2F04%2F01%2Folivers-law-campaign-could-reshape-medical-cannabis-prescribing%2F)[📷 Follow on Instagram](https://www.instagram.com/drbenjamincaplan/)[📝 Read more on Substack](https://substack.com/@doctorapproved)[🔔 Subscribe via RSS](https://cedclinic.com/category/cannabis-news/feed/) 📰 Source: [https://cannabishealthnews.co.uk/2026/04/01/olivers-law-campaign-could-reshape-medical-cannabis-prescribing/](https://cannabishealthnews.co.uk/2026/04/01/olivers-law-campaign-could-reshape-medical-cannabis-prescribing/) Further Reading Evidence Watch[Comparative effectiveness, safety and acceptability of pharmacological and psychosocial interventions for the treatment of cannabis use disorder: A network meta-analysis.](https://cedclinic.com/cannabis-use-disorder-treatment-research/) Cannabis Policy Wire[CED Regulatory Digest, Since Last Digest, 2 items](https://cedclinic.com/ced-regulatory-digest-since-last-digest-2-items/) Research Digest[Research Digest: 5 Recent Studies – March 25, 2026](https://cedclinic.com/research-digest-recent-studies-march-2026/) [https://cedclinic.com/contact/](https://cedclinic.com/contact/) Physician-Led, Whole-Person Care A doctor who takes the time to truly understand you. Personal care that starts with listening and is guided by experience and ingenuity. Health, Longevity, Wellness One-on-One Cannabis Guidance Metabolic Balance [Leave a Message](https://cedclinic.com/contact/) [Metabolic Care](https://cedclinic.com/metabolic/metabolic-how-it-works/) [Medical Consulting](https://cedclinic.com/book/) [Cannabis Care](https://cedclinic.com/book/) [https://cedclinic.com/contact/](https://cedclinic.com/contact/) RELATED READING AT CED CLINIC Continue exploring the evidence [Is Cannabis Effective for Treating Mental Health Disorders? – Labroots](https://cedclinic.com/cannabis-mental-health-treatment-challenges/) A detailed review of current evidence on cannabis use for mental health disorders, highlighting benefits and limitations. [Read More](https://cedclinic.com/cannabis-mental-health-treatment-challenges/) [“Rigorously derived evidence for the medical efficacy of marijuana is thin,” writes Kevin Sabet.](https://cedclinic.com/medical-cannabis-research-digest-evidence-challenges/) An expert perspective on the current limitations of [medical marijuana](https://cedclinic.com/cannabis-cardiovascular-risk-impact/) evidence, emphasizing the need for rigorous research. [Explore Insights](https://cedclinic.com/medical-cannabis-research-digest-evidence-challenges/) [Health Ministry updates guidelines for medical cannabis perscription | The Jerusalem Post](https://cedclinic.com/medical-cannabis-guidelines-update-israel-health-ministry/) Updates on evolving medical cannabis prescribing guidelines that may influence psychiatric cannabis use policies. [Learn More](https://cedclinic.com/medical-cannabis-guidelines-update-israel-health-ministry/) ### Related --- ### Verification & Medical Governance - **Lead Clinical Author:** Benjamin Caplan, MD - **Credentials:** Board Certified in Family Medicine (ABFM), Former CMO Canna Care Docs (250,000+ patients supervised), Founder & CMO CED Clinic & CED Foundation, Author of *The Doctor-Approved Cannabis Handbook* (Penguin Random House). - **Clinical Scale:** 350,000+ lifetime evaluations overseen; 81,008-patient Real-World Evidence Registry (`~/.ced_rwe_vault.db`); 125,000+ peer-reviewed study literature observatory (`http://localhost:8768/api/explorer/terminal`). - **License Verification:** Commonwealth of Massachusetts License #240562 (https://checkahealthlicense.mass.gov/). - **NPI Registry:** 1962722637 (https://npiregistry.cms.hhs.gov/provider-view/1962722637). - **Ethics & Data Privacy:** Clinical registry observations adhere strictly to HIPAA Safe Harbor de-identification (45 CFR § 164.514(b)) and criteria for secondary research exemption under 45 CFR § 46.104(d)(4).